Energenesis Biomedical Co (TPE:6657) Market Cap: NT$3,111.94 Mil (As of Jul. 02, 2026)


TPE:6657 Energenesis Biomedical Co Ltd TPE:6657
64 GF Score
Price NT$35.40
GF Value NT$51.33
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Energenesis Biomedical Co Market Cap?

Energenesis Biomedical Co TPE:6657 -0.84% 64 Market Cap is NT$3,111.94 Mil as of Jul. 02, 2026. GuruFocus rates TPE:6657 with a GF Score™ of 64/100 and a GF Value™ of NT$51.33 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,427 Biotechnology companies, Energenesis Biomedical Co ranks worse than 52.91% on this metric.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Energenesis Biomedical Co's share price for the quarter that ended in Dec. 2025 was NT$43. Energenesis Biomedical Co's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 87.98 Mil. Therefore, Energenesis Biomedical Co's market cap for the quarter that ended in Dec. 2025 was NT$3,783.05 Mil.

Energenesis Biomedical Co's quarterly market cap declined from Jun. 2025 (NT$5,966.68 Mil) to Sep. 2025 (NT$4,725.47 Mil) and declined from Sep. 2025 (NT$4,725.47 Mil) to Dec. 2025 (NT$3,783.05 Mil).

Energenesis Biomedical Co's annual market cap declined from Dec. 2023 (NT$4,591.89 Mil) to Dec. 2024 (NT$3,921.05 Mil) and declined from Dec. 2024 (NT$3,921.05 Mil) to Dec. 2025 (NT$3,783.05 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Energenesis Biomedical Co's Enterprise Value for Today is NT$2,288.68 Mil.


Energenesis Biomedical Co  (TPE:6657) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Energenesis Biomedical Co Market Cap Related Terms


Energenesis Biomedical Co Market Cap Historical Data

* Premium members only.

The historical data trend for Energenesis Biomedical Co's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Energenesis Biomedical Co Market Cap Chart

Energenesis Biomedical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,990.02 2,840.91 4,591.89 3,921.05 3,783.05

Energenesis Biomedical Co Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,921.05 5,849.45 5,966.68 4,725.47 3,783.05

TPE:6657 vs VRTX, REGN, ALNY: Market Cap Comparison

For the Biotechnology subindustry, Energenesis Biomedical Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Energenesis Biomedical Co Market Cap vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Energenesis Biomedical Co's Market Cap distribution charts can be found below:

* The bar in red indicates where Energenesis Biomedical Co's Market Cap falls into.


TPE:6657
64GF Score
Energenesis Biomedical Co Ltd TPE:6657
Market Cap is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Energenesis Biomedical Co Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Energenesis Biomedical Co's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as

Market Cap (A: Dec. 2025 )=Share Price (A: Dec. 2025 )*Shares Outstanding (EOP) (A: Dec. 2025 )
=NT$43*87.978
=NT$3,783.05

Energenesis Biomedical Co's Market Cap for the quarter that ended in Dec. 2025 is calculated as

Market Cap (Q: Dec. 2025 )=Share Price (Q: Dec. 2025 )*Shares Outstanding (EOP) (Q: Dec. 2025 )
=NT$43*87.978
=NT$3,783.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of NT$3,111.94 Mil mean?
Energenesis Biomedical Co (TPE:6657) has a Market Cap of NT$3,111.94 Mil as of Jul. 02, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Energenesis Biomedical Co and its competitors. According to the industry distribution chart, Energenesis Biomedical Co ranks #755 out of 1427 companies in the Biotechnology industry, placing it in the top 52.9%.
Is Energenesis Biomedical Co's Market Cap too high?
Energenesis Biomedical Co's current Market Cap is NT$3,111.94 Mil. Based on the distribution chart, Energenesis Biomedical Co ranks #755 out of 1427 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Energenesis Biomedical Co has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Energenesis Biomedical Co's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Energenesis Biomedical Co ranks #755 out of 1427 companies for Market Cap. This places Energenesis Biomedical Co in the lower half of its industry. The industry median Market Cap is 119.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.04, based on 1,427 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Energenesis Biomedical Co and its competitors. For the Biotechnology industry, the median Market Cap is 119.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Energenesis Biomedical Co's current Market Cap is NT$3,111.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Energenesis Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Energenesis Biomedical Co (TPE:6657) is currently considered Possible Value Trap. The stock's GF Value™ is NT$51.33, compared to a current price of NT$35.40 — trading 31% below its estimated fair value. The current Market Cap is NT$3,111.94 Mil. Energenesis Biomedical Co's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Energenesis Biomedical Co (TPE:6657), the current Market Cap is NT$3,111.94 Mil as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Energenesis Biomedical Co (TPE:6657) Overvalued in 2026?

Based on GuruFocus' analysis, Energenesis Biomedical Co stock appears to be undervalued. The current stock price of NT$35.40 is trading 31% below its estimated GF Value™ of NT$51.33. GuruFocus considers Energenesis Biomedical Co to be Possible Value Trap.

Key valuation signals for TPE:6657:

  • Market Cap: NT$3,111.94 Mil
  • GF Value™: NT$51.33 vs. price of NT$35.40 (31% below fair value)
  • GF Score™: 64/100 with 3 warning signs

No single metric tells the full story. See the TPE:6657 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Energenesis Biomedical Co Business Description

Address No. 21, Lane 583, Ruiguang Road, 6th Floor -3, Neihu District, Taipei, TWN, 11492
Energenesis Biomedical Co Ltd is a biomedicine company. The company is engaged in businesses related to biological experimentation and analysis, as well as new drugs development. The company uses its ENERGI drug development platform to activate AMP-activated protein kinase (AMPK), a key enzyme in cell energy regulation, as a means of developing disease treatments. The product pipeline of the company consists of ENERGI-F703, a diabetic foot ulcers treatment gel; ENERGI-F701, a product developed for male hair loss; ENERGI-F704, an inflammatory bowel disease treatment; and ENERGI-F711, a burn cream,F708, Asthama treatment, and others.
64GF Score

Get the complete analysis for TPE:6657

Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$35.40
Price
NT$51.33
GF Value